SHCSotera Health Company

$18.06+16% 1Y

$18.06

$13.1352 weeks$19.58

Is the price fair?

Fair

The yardsticks disagree: cheap against its own 5-year P/E range (13th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.

1 good, 1 to watch, 1 without data

What the price assumes~+16% a yearderived · Jun 30, 2026

Priced for ~16% a year FCF growth. The price demands more than its three-year revenue growth of 8% a year, priced for acceleration.

Vs its own P/E rangecheaper than 87% of its own historyderived

Cheap vs its own history: P/E 31.7 vs a 66.1 median over 16 quarters (−52% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 71% of the market

FCF yieldbehind 81% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What SHC's price assumes

Sotera Health Company trades at 31.7× earnings against 35.2× for the median Diagnostics & Research name, cheaper than its own group.

31.7

Trailing P/E · Diagnostics & Research median 35.2 · cheaper than the typical name in its group

Price / sales: 4.01
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 2.3%
Free cash flow yield · Diagnostics & Research median 3.7%
Growth the price implies: +16%
Growth the price implies · The price pays for +16% free cash flow growth a year for a decade; revenue has grown +7.6% a year over the last three.